Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
74 Results for "
esterification
" in MedChemExpress (MCE) Product Catalog:
Products (74)
74 Results for "esterification" in MCE Product Catalog:
Cat. No.: HY-183003D
Cat. No.: HY-183163
Cat. No.: HY-183163A
Cat. No.: HY-183163B
Cat. No.: HY-183163C
Cat. No.: HY-183163D
Cat. No.: HY-186296
CAS No.: 59000-66-7
Target:
Research Areas:
Cholestanol stearate serves as a substrate for plasma lecithin:cholesterol acyltransferase (LCAT), with an esterification rate of approximately 70% that of cholesterol. Cholestanol stearate contains both hydrophilic and lipophilic groups, and its components are related to the structural substances of natural products. Cholestanol stearate can be used in studies related to cerebrotendinous xanthomatosis and familial lecithin:cholesterol acyltransferase deficiency .
Cat. No.: HY-W015310
CAS No.: 659-70-1
Category:
Cat. No.: HY-W749394
CAS No.: 2707945-47-7
Cat. No.: HY-L265
558 compounds
Cholesterol is a crucial lipid that maintains cell membrane structure, serves as a precursor for the synthesis of steroid hormones and bile acids, and plays an important role in cell signal transduction and membrane function regulation. Intracellular cholesterol levels are precisely controlled by multiple processes, including synthesis, uptake, transport, esterification, storage, and efflux. Dysregulation of cholesterol metabolism is closely associated with diseases such as atherosclerosis, fatty liver disease, metabolic syndrome, and various cancers.
The Cholesterol Metabolism Compound Library contains 558 compounds and focuses on cholesterol metabolism and homeostatic regulation. It provides an efficient tool for mechanistic studies of cholesterol metabolism and for drug discovery in metabolism‑related diseases.
Cat. No.: HY-138198A
Target:
Research Areas:
YIC-C8-434 is an orally active ACAT inhibitor. YIC-C8-434 selectively blocks cholesterol esterification in intestinal epithelial cells and hepatocytes without affecting the production of triglycerides or phospholipids. YIC-C8-434 effectively reduces intracellular cholesteryl ester levels and induces an increase in lipid droplet volume, exhibiting excellent cholesterol-lowering activity and safety. YIC-C8-434 disrupts the assembly of hepatitis C virus (HCV) virions, reduces HCV RNA synthesis and viral particle release. YIC-C8-434 can be used in studies related to hepatitis C virus infection .
Cat. No.: HY-184414
Target:
Research Areas:
BMS-135-L-Lys is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys can be used in related research on colon cancer and lung cancer .
Cat. No.: HY-184414A
Target:
Research Areas:
BMS-135-L-Lys TFA is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys TFA achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys TFA is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys TFA can be used in related research on colon cancer and lung cancer .
Cat. No.: HY-184414B
Target:
Research Areas:
BMS-135-L-Lys dihydrochloride is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys dihydrochloride achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys dihydrochloride is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys dihydrochloride can be used in related research on colon cancer and lung cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
